⌘K
t
ANGLE plc announced it will release its interim results for the six months ended 30 June 2024 on Thursday, 26 September 2024. A meeting for analysts will be held at 11:00 am BST on the same date at the offices of Berenberg, 60 Threadneedle Street, London EC2R 8HP. A live webcast of this meeting will also be accessible.
| Date | 17 Sept 2024 |
| Time | 07:00:11 |
| Category | Results |
| ID | 4068E |
|
For immediate release |
17 September 2024 |
ANGLE plc ("the Company")
Notice of Interim Results and Webcast
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, will be releasing its interim results for the six months ended 30 June 2024 on Thursday 26 September 2024.
A meeting for analysts will be held at 11:00 am BST on Thursday 26 September 2024 at the offices of Berenberg, 60 Threadneedle Street, London EC2R 8HP.
A live webcast of the analyst meeting can be accessed via ANGLE's Investor Centre page, https://angleplc.com/investor-relations/corporate-presentations/, with Q&A participation reserved for analysts only. Please register in advance and log on to the webcast approximately 5 minutes before 11:00 am on the day of the results. A recording of the webcast will be made available on ANGLE's website following the results meeting.
For further information:
|
ANGLE plc |
+44 (0) 1483 343434 |
|
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
|
|
|
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser
|
+44 (0) 20 3207 7800 |
|
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) |
+44 (0) 203 727 1000 +1 (212) 850 5624 |
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology, known as the Parsortix® PC1 system, enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE's GCLP-compliant laboratories in the UK. Services include custom made assay development and clinical trial testing for pharma.
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com